药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2015年
3期
235-237
,共3页
揭琼%袁馨%陈美灵%吴玉林
揭瓊%袁馨%陳美靈%吳玉林
게경%원형%진미령%오옥림
大鼠过敏性鼻炎%枸地氯雷他定注射液%鼻腔灌洗液%炎症介质%炎症细胞
大鼠過敏性鼻炎%枸地氯雷他定註射液%鼻腔灌洗液%炎癥介質%炎癥細胞
대서과민성비염%구지록뢰타정주사액%비강관세액%염증개질%염증세포
Allergic rhinitis in rats%Desloratadine citrate disodium injection (DLC)%Nasal lavage fluid%Inflammatory mediators%Inflammatory cells
目的：研究枸地氯雷他定注射液对卵白蛋白（OVA）致大鼠过敏性鼻炎的鼻部症状及鼻腔灌洗液PGD2、LTC4含量和炎症细胞浸润的影响。方法：采用OVA建立大鼠过敏性鼻炎模型，将造模成功的SD雄性大鼠随机分成5组：模型组、枸地氯雷他定注射液（简称枸地）低、中、高剂量组，阳性药马来酸氯苯那敏注射液（扑尔敏）组。另随机取正常大鼠设正常组。造模第22天，模型组和正常组静注生理盐水；枸地低、中、高剂量组分别静注0.3、0.6、1.2 mg·kg-1；扑尔敏组静注0.6 mg·kg-1。各组每天一次用药，连续5天，同时隔天以OVA滴鼻以维持过敏状态。于最后一次给药半小时后OVA滴鼻激发观察30 min内大鼠抓鼻、喷嚏及流涕情况，采取积分法记录上述症状程度；2 h后收集大鼠鼻腔灌洗液（NLF）测定PGD2、LTC4含量及炎症细胞数量。结果与结论：枸地组可显著改善过敏性鼻炎大鼠鼻部症状，且能减少NLF中炎症介质PGD2、LTC4含量及炎症细胞数量，改善过敏性鼻炎大鼠鼻部症状，同时也能抑制白细胞浸润，减轻晚期慢性炎症反应。
目的：研究枸地氯雷他定註射液對卵白蛋白（OVA）緻大鼠過敏性鼻炎的鼻部癥狀及鼻腔灌洗液PGD2、LTC4含量和炎癥細胞浸潤的影響。方法：採用OVA建立大鼠過敏性鼻炎模型，將造模成功的SD雄性大鼠隨機分成5組：模型組、枸地氯雷他定註射液（簡稱枸地）低、中、高劑量組，暘性藥馬來痠氯苯那敏註射液（撲爾敏）組。另隨機取正常大鼠設正常組。造模第22天，模型組和正常組靜註生理鹽水；枸地低、中、高劑量組分彆靜註0.3、0.6、1.2 mg·kg-1；撲爾敏組靜註0.6 mg·kg-1。各組每天一次用藥，連續5天，同時隔天以OVA滴鼻以維持過敏狀態。于最後一次給藥半小時後OVA滴鼻激髮觀察30 min內大鼠抓鼻、噴嚏及流涕情況，採取積分法記錄上述癥狀程度；2 h後收集大鼠鼻腔灌洗液（NLF）測定PGD2、LTC4含量及炎癥細胞數量。結果與結論：枸地組可顯著改善過敏性鼻炎大鼠鼻部癥狀，且能減少NLF中炎癥介質PGD2、LTC4含量及炎癥細胞數量，改善過敏性鼻炎大鼠鼻部癥狀，同時也能抑製白細胞浸潤，減輕晚期慢性炎癥反應。
목적：연구구지록뢰타정주사액대란백단백（OVA）치대서과민성비염적비부증상급비강관세액PGD2、LTC4함량화염증세포침윤적영향。방법：채용OVA건립대서과민성비염모형，장조모성공적SD웅성대서수궤분성5조：모형조、구지록뢰타정주사액（간칭구지）저、중、고제량조，양성약마래산록분나민주사액（복이민）조。령수궤취정상대서설정상조。조모제22천，모형조화정상조정주생리염수；구지저、중、고제량조분별정주0.3、0.6、1.2 mg·kg-1；복이민조정주0.6 mg·kg-1。각조매천일차용약，련속5천，동시격천이OVA적비이유지과민상태。우최후일차급약반소시후OVA적비격발관찰30 min내대서조비、분체급류체정황，채취적분법기록상술증상정도；2 h후수집대서비강관세액（NLF）측정PGD2、LTC4함량급염증세포수량。결과여결론：구지조가현저개선과민성비염대서비부증상，차능감소NLF중염증개질PGD2、LTC4함량급염증세포수량，개선과민성비염대서비부증상，동시야능억제백세포침윤，감경만기만성염증반응。
Objective: To study the effect of desloratadine citrate disodium injections (DLC) on ovalbumin-induced allergic rhinitis in rats, including the rhinitis symptoms, PGD2 and LTC4 levels and inflammatory cell infiltration in nasal lavage fluid (NLF). Methods: Ovalbumin-induced allergic rhinitis male SD rats were randomly divided in five groups: model group, DLC low, medium and high dose groups, and chlorphenamine maleate injectlon (CHM) group as positive group. In addition, the normal rats were also recorded. From the 22nd day of being modeled, rats of the model and normal groups were given iv saline, the DLC low, medium and high dose groups were given DLC at 0.3, 0.6 and 1.2 mg·kg-1, CHM group were given CHM at 0.6 mg·kg-1, all the iv treatments were once a day for five days. Rats were topically sensitized by instilling ovalbumin solution into the bilateral nasal cavities on alternate days. Symptoms of rhinitis were observed continuously for 30 min at the last time for administration and topically sensitization, taking the scoring method to record the symptoms of rhinitis. Two hours after the intranasal challenge, NLF was collected, PGD2 and LTC4 levels and inflammatory cellular infiltration were evaluated, respectively. Results and Conclusion: DLC significantly attenuated ovalbumin-induced rhinitis symptoms and caused a significant reduction in PGD2 and LTC4 levels and inflammatory cellular infiltration.
